Blood test may predict nausea from breast cancer treatment

NCT ID NCT07465172

Not yet recruiting Knowledge-focused Sponsor: Breast Cancer Trials, Australia and New Zealand Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 150 breast cancer patients starting T-DXd, a drug that often causes nausea, vomiting, and weight loss. Researchers will measure blood levels of a hormone called GDF-15 before and during treatment to see if changes in GDF-15 are linked to these side effects. If a link is found, it could help doctors identify patients at risk and manage side effects better in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which breast cancer patients will have severe nausea or vomiting from T-DXd, allowing for better supportive care.
What could go wrong: This is an observational study, not a treatment trial. It only looks for a link between GDF-15 and side effects, so it won't directly improve outcomes. The results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma Nausea Vomiting Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Lake Macquarie Private Hospital

Newcastle, New South Wales, 2290, Australia
Okayama University Hospital

Okayama, 700-8558, Japan
Peter MacCallum Cancer Centre

Melbourne, Victoria, 3000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.